Trials / Completed
CompletedNCT00928551
Comparative Formulation Study of Vabicaserin
A Randomized, Open-Label, Single-Dose, 3-Period Crossover, Comparative Study of a Modified Formulation of Vabicaserin (SCA-136) Versus the Reference Formulation in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will compare two different formulations of vabicaserin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vabicaserin |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-06-26
- Last updated
- 2009-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00928551. Inclusion in this directory is not an endorsement.